Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...
ZURICH (Reuters) - Novartis AG's Aclasta was more effective than Procter & Gamble Co's Actonel in increasing bone mass in patients with the bone-thinning disease osteoporosis, a study showed. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results